Annual EBIT
$64.32 M
+$26.51 M+70.10%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual earnings before interest & taxes is currently $64.32 million, with the most recent change of +$26.51 million (+70.10%) on 31 December 2023. During the last 3 years, it has risen by +$35.61 million (+124.04%). LGND annual EBIT is now -92.27% below its all-time high of $876.12 million.LGND EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
$10.96 M
+$75.08 M+117.08%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly earnings before interest & taxes is currently $10.96 million, with the most recent change of +$75.08 million (+117.08%) on 30 September 2024. Over the past year, it has increased by +$23.10 million (+190.22%). LGND quarterly EBIT is now -98.71% below its all-time high of $851.62 million, reached on 31 March 2019.LGND Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
$77.65 M
+$23.10 M+42.34%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated TTM earnings before interest & taxes is currently $77.65 million, with the most recent change of +$23.10 million (+42.34%) on 30 September 2024. Over the past year, it has increased by +$6.18 million (+8.65%). LGND TTM EBIT is now -92.35% below its all-time high of $1.01 billion, reached on 31 March 2019.LGND TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +70.1% | +190.2% | +8.7% |
| 3 y3 years | +124.0% | -44.4% | -14.7% |
| 5 y5 years | -71.0% | +200.7% | -90.2% |
LGND EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -30.0% | +124.0% | -90.4% | +117.1% | -36.4% | +117.0% |
| 5 y | 5 years | -92.3% | +124.0% | -90.4% | +117.1% | -90.7% | +288.9% |
| alltime | all time | -92.3% | +166.1% | -98.7% | +114.9% | -92.3% | +179.2% |
Ligand Pharmaceuticals Incorporated EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.96 M(-117.1%) | $77.65 M(+42.3%) |
| June 2024 | - | -$64.12 M(-156.5%) | $54.55 M(-55.3%) |
| Mar 2024 | - | $113.59 M(+559.3%) | $122.13 M(+89.9%) |
| Dec 2023 | $64.32 M(+70.1%) | $17.23 M(-241.9%) | $64.32 M(-10.0%) |
| Sept 2023 | - | -$12.14 M(-451.5%) | $71.47 M(-25.8%) |
| June 2023 | - | $3.46 M(-93.8%) | $96.30 M(-5.5%) |
| Mar 2023 | - | $55.78 M(+128.8%) | $101.94 M(+169.6%) |
| Dec 2022 | $37.81 M(-58.8%) | $24.38 M(+92.2%) | $37.81 M(+5.7%) |
| Sept 2022 | - | $12.69 M(+39.4%) | $35.78 M(-16.4%) |
| June 2022 | - | $9.10 M(-208.9%) | $42.79 M(-40.5%) |
| Mar 2022 | - | -$8.36 M(-137.4%) | $71.87 M(-21.7%) |
| Dec 2021 | $91.82 M(+219.9%) | $22.35 M(+13.4%) | $91.82 M(+0.8%) |
| Sept 2021 | - | $19.70 M(-48.4%) | $91.06 M(+37.9%) |
| June 2021 | - | $38.18 M(+229.3%) | $66.02 M(+6.2%) |
| Mar 2021 | - | $11.60 M(-46.3%) | $62.17 M(+116.6%) |
| Dec 2020 | $28.71 M(-96.6%) | $21.59 M(-504.0%) | $28.71 M(+268.9%) |
| Sept 2020 | - | -$5.34 M(-115.6%) | $7.78 M(+246.4%) |
| June 2020 | - | $34.33 M(-257.0%) | $2.25 M(-105.5%) |
| Mar 2020 | - | -$21.87 M(-3418.2%) | -$41.10 M(-104.9%) |
| Dec 2019 | $832.38 M(+275.6%) | $659.00 K(-106.1%) | $832.38 M(+4.7%) |
| Sept 2019 | - | -$10.88 M(+20.7%) | $795.08 M(-11.3%) |
| June 2019 | - | -$9.02 M(-101.1%) | $896.38 M(-11.6%) |
| Mar 2019 | - | $851.62 M(-2423.9%) | $1.01 B(+357.8%) |
| Dec 2018 | $221.61 M(+213.5%) | -$36.65 M(-140.5%) | $221.60 M(-24.2%) |
| Sept 2018 | - | $90.43 M(-17.1%) | $292.35 M(+34.5%) |
| June 2018 | - | $109.03 M(+85.5%) | $217.38 M(+81.2%) |
| Mar 2018 | - | $58.79 M(+72.4%) | $119.99 M(+68.0%) |
| Dec 2017 | $70.69 M(+239.8%) | $34.10 M(+120.6%) | $71.41 M(+112.6%) |
| Sept 2017 | - | $15.46 M(+32.8%) | $33.59 M(+42.3%) |
| June 2017 | - | $11.64 M(+13.9%) | $23.59 M(+48.2%) |
| Mar 2017 | - | $10.22 M(-374.0%) | $15.92 M(-23.5%) |
| Dec 2016 | $20.80 M(-23.9%) | -$3.73 M(-168.2%) | $20.80 M(-40.2%) |
| Sept 2016 | - | $5.47 M(+37.7%) | $34.76 M(-9.1%) |
| June 2016 | - | $3.97 M(-73.7%) | $38.24 M(-1.6%) |
| Mar 2016 | - | $15.10 M(+47.6%) | $38.85 M(+42.2%) |
| Dec 2015 | $27.33 M(+32.0%) | $10.23 M(+14.4%) | $27.33 M(+0.1%) |
| Sept 2015 | - | $8.94 M(+95.1%) | $27.30 M(+23.7%) |
| June 2015 | - | $4.58 M(+28.3%) | $22.07 M(+16.3%) |
| Mar 2015 | - | $3.57 M(-65.0%) | $18.98 M(-8.4%) |
| Dec 2014 | $20.71 M(+29.6%) | $10.20 M(+174.6%) | $20.71 M(+20.8%) |
| Sept 2014 | - | $3.71 M(+148.6%) | $17.14 M(+2.5%) |
| June 2014 | - | $1.49 M(-71.8%) | $16.72 M(-3.2%) |
| Mar 2014 | - | $5.30 M(-20.0%) | $17.27 M(+8.0%) |
| Dec 2013 | $15.98 M(+1215.5%) | $6.63 M(+101.0%) | $15.98 M(+14.3%) |
| Sept 2013 | - | $3.30 M(+61.8%) | $13.98 M(+48.4%) |
| June 2013 | - | $2.04 M(-49.3%) | $9.43 M(+57.4%) |
| Mar 2013 | - | $4.02 M(-13.1%) | $5.99 M(+392.8%) |
| Dec 2012 | $1.22 M(+378.3%) | $4.63 M(-467.1%) | $1.22 M(-21.3%) |
| Sept 2012 | - | -$1.26 M(-10.0%) | $1.54 M(+9.5%) |
| June 2012 | - | -$1.40 M(+86.3%) | $1.41 M(-56.0%) |
| Mar 2012 | - | -$752.00 K(-115.2%) | $3.20 M(+1086.7%) |
| Dec 2011 | $254.00 K(-101.7%) | $4.96 M(-455.4%) | $270.00 K(-104.3%) |
| Sept 2011 | - | -$1.40 M(-455.0%) | -$6.26 M(-61.6%) |
| June 2011 | - | $393.00 K(-110.7%) | -$16.29 M(-0.3%) |
| Mar 2011 | - | -$3.69 M(+135.1%) | -$16.33 M(+6.4%) |
| Dec 2010 | -$15.35 M(+59.8%) | -$1.57 M(-86.3%) | -$15.35 M(+20.5%) |
| Sept 2010 | - | -$11.43 M(-3383.9%) | -$12.73 M(+5532.7%) |
| June 2010 | - | $348.00 K(-112.9%) | -$226.00 K(-95.5%) |
| Mar 2010 | - | -$2.70 M(-357.6%) | -$5.01 M(-47.8%) |
| Dec 2009 | -$9.60 M | $1.05 M(-2.7%) | -$9.60 M(-88.6%) |
| Sept 2009 | - | $1.08 M(-124.3%) | -$84.07 M(-8.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$4.43 M(-39.2%) | -$91.50 M(-1.3%) |
| Mar 2009 | - | -$7.29 M(-90.1%) | -$92.70 M(-4.3%) |
| Dec 2008 | -$97.31 M(+84.6%) | -$73.43 M(+1055.4%) | -$96.86 M(+303.2%) |
| Sept 2008 | - | -$6.36 M(+12.8%) | -$24.02 M(-9.0%) |
| June 2008 | - | -$5.63 M(-50.8%) | -$26.39 M(-24.9%) |
| Mar 2008 | - | -$11.45 M(+1846.6%) | -$35.12 M(-33.4%) |
| Dec 2007 | -$52.72 M(-32.5%) | -$588.00 K(-93.3%) | -$52.72 M(-30.1%) |
| Sept 2007 | - | -$8.72 M(-39.3%) | -$75.39 M(-15.4%) |
| June 2007 | - | -$14.37 M(-50.5%) | -$89.12 M(-4.0%) |
| Mar 2007 | - | -$29.04 M(+24.9%) | -$92.81 M(+18.9%) |
| Dec 2006 | -$78.08 M(+79.0%) | -$23.26 M(+3.6%) | -$78.08 M(-0.4%) |
| Sept 2006 | - | -$22.45 M(+24.3%) | -$78.38 M(+29.5%) |
| June 2006 | - | -$18.06 M(+26.2%) | -$60.52 M(+23.6%) |
| Mar 2006 | - | -$14.31 M(-39.2%) | -$48.97 M(-2.9%) |
| Dec 2005 | -$43.63 M(+183.7%) | -$23.56 M(+413.4%) | -$50.42 M(-535.9%) |
| Sept 2005 | - | -$4.59 M(-29.5%) | $11.57 M(+1995.8%) |
| June 2005 | - | -$6.51 M(-58.7%) | $552.00 K(-104.6%) |
| Mar 2005 | - | -$15.77 M(-141.0%) | -$12.07 M(-21.5%) |
| Dec 2004 | -$15.38 M(-79.2%) | $38.44 M(-346.3%) | -$15.38 M(-84.3%) |
| Sept 2004 | - | -$15.61 M(-18.4%) | -$98.00 M(+8.2%) |
| June 2004 | - | -$19.13 M(+0.2%) | -$90.59 M(+12.5%) |
| Mar 2004 | - | -$19.08 M(-56.8%) | -$80.54 M(+8.8%) |
| Dec 2003 | -$74.02 M(+68.8%) | -$44.19 M(+439.3%) | -$74.02 M(+34.4%) |
| Sept 2003 | - | -$8.19 M(-9.7%) | -$55.07 M(+2.6%) |
| June 2003 | - | -$9.07 M(-27.8%) | -$53.66 M(-0.7%) |
| Mar 2003 | - | -$12.56 M(-50.2%) | -$54.07 M(+23.3%) |
| Dec 2002 | -$43.85 M(+89.5%) | -$25.25 M(+272.0%) | -$43.85 M(+107.3%) |
| Sept 2002 | - | -$6.79 M(-28.4%) | -$21.16 M(+11.8%) |
| June 2002 | - | -$9.47 M(+303.7%) | -$18.93 M(+10.6%) |
| Mar 2002 | - | -$2.35 M(-7.9%) | -$17.12 M(-26.0%) |
| Dec 2001 | -$23.14 M(-49.6%) | -$2.55 M(-44.1%) | -$23.14 M(-22.9%) |
| Sept 2001 | - | -$4.56 M(-40.5%) | -$30.00 M(-16.4%) |
| June 2001 | - | -$7.67 M(-8.4%) | -$35.88 M(-14.1%) |
| Mar 2001 | - | -$8.37 M(-11.1%) | -$41.79 M(-7.1%) |
| Dec 2000 | -$45.88 M(-25.1%) | -$9.41 M(-9.8%) | -$44.98 M(-13.9%) |
| Sept 2000 | - | -$10.44 M(-23.1%) | -$52.23 M(-8.3%) |
| June 2000 | - | -$13.58 M(+17.5%) | -$56.93 M(-5.4%) |
| Mar 2000 | - | -$11.55 M(-30.6%) | -$60.15 M(-1.9%) |
| Dec 1999 | -$61.29 M(-11.9%) | -$16.66 M(+10.1%) | -$61.30 M(-10.6%) |
| Sept 1999 | - | -$15.13 M(-9.9%) | -$68.53 M(-2.5%) |
| June 1999 | - | -$16.80 M(+32.3%) | -$70.30 M(+0.9%) |
| Mar 1999 | - | -$12.70 M(-46.9%) | -$69.70 M(+0.1%) |
| Dec 1998 | -$69.60 M(+126.0%) | -$23.90 M(+41.4%) | -$69.60 M(+46.2%) |
| Sept 1998 | - | -$16.90 M(+4.3%) | -$47.60 M(+16.1%) |
| June 1998 | - | -$16.20 M(+28.6%) | -$41.00 M(+19.9%) |
| Mar 1998 | - | -$12.60 M(+563.2%) | -$34.20 M(+11.4%) |
| Dec 1997 | -$30.80 M(-6.4%) | -$1.90 M(-81.6%) | -$30.70 M(-22.1%) |
| Sept 1997 | - | -$10.30 M(+9.6%) | -$39.40 M(+9.1%) |
| June 1997 | - | -$9.40 M(+3.3%) | -$36.10 M(+1.4%) |
| Mar 1997 | - | -$9.10 M(-14.2%) | -$35.60 M(+9.2%) |
| Dec 1996 | -$32.90 M(+32.1%) | -$10.60 M(+51.4%) | -$32.60 M(+10.9%) |
| Sept 1996 | - | -$7.00 M(-21.3%) | -$29.40 M(-2.3%) |
| June 1996 | - | -$8.90 M(+45.9%) | -$30.10 M(+90.5%) |
| Mar 1996 | - | -$6.10 M(-17.6%) | -$15.80 M(+14.5%) |
| Dec 1995 | -$24.90 M(+19.1%) | -$7.40 M(-3.9%) | -$13.80 M(+23.2%) |
| Sept 1995 | - | -$7.70 M(-242.6%) | -$11.20 M(+34.9%) |
| June 1995 | - | $5.40 M(-231.7%) | -$8.30 M(-57.2%) |
| Mar 1995 | - | -$4.10 M(-14.6%) | -$19.40 M(-7.2%) |
| Dec 1994 | -$20.90 M | -$4.80 M(0.0%) | -$20.90 M(+29.8%) |
| Sept 1994 | - | -$4.80 M(-15.8%) | -$16.10 M(+42.5%) |
| June 1994 | - | -$5.70 M(+1.8%) | -$11.30 M(+101.8%) |
| Mar 1994 | - | -$5.60 M | -$5.60 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual earnings before interest & taxes?
- What is the all time high annual EBIT for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual EBIT year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly EBIT year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM EBIT year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual earnings before interest & taxes?
The current annual EBIT of LGND is $64.32 M
What is the all time high annual EBIT for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual earnings before interest & taxes is $876.12 M
What is Ligand Pharmaceuticals Incorporated annual EBIT year-on-year change?
Over the past year, LGND annual earnings before interest & taxes has changed by +$26.51 M (+70.10%)
What is Ligand Pharmaceuticals Incorporated quarterly earnings before interest & taxes?
The current quarterly EBIT of LGND is $10.96 M
What is the all time high quarterly EBIT for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly earnings before interest & taxes is $851.62 M
What is Ligand Pharmaceuticals Incorporated quarterly EBIT year-on-year change?
Over the past year, LGND quarterly earnings before interest & taxes has changed by +$23.10 M (+190.22%)
What is Ligand Pharmaceuticals Incorporated TTM earnings before interest & taxes?
The current TTM EBIT of LGND is $77.65 M
What is the all time high TTM EBIT for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM earnings before interest & taxes is $1.01 B
What is Ligand Pharmaceuticals Incorporated TTM EBIT year-on-year change?
Over the past year, LGND TTM earnings before interest & taxes has changed by +$6.18 M (+8.65%)